NASDAQ:VRCAVerrica Pharmaceuticals Stock Price, Forecast & News

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VRCA shares have increased by 9.1% and is now trading at $11.48. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verrica Pharmaceuticals.

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Verrica Pharmaceuticals.

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) posted its earnings results on Thursday, May, 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.01. View Verrica Pharmaceuticals' earnings history.

2 Wall Street analysts have issued twelve-month price targets for Verrica Pharmaceuticals' shares. Their forecasts range from $20.00 to $24.00. On average, they anticipate Verrica Pharmaceuticals' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 91.6% from the stock's current price. View analysts' price targets for Verrica Pharmaceuticals.

News stories about VRCA stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Verrica Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the near future. View the latest news aboutVerrica Pharmaceuticals.

Verrica Pharmaceuticals saw a decline in short interest in April. As of April 30th, there was short interest totaling 754,900 shares, a decline of 5.3% from the April 15th total of 797,100 shares. Based on an average trading volume of 67,900 shares, the short-interest ratio is currently 11.1 days. Currently, 5.9% of the shares of the stock are sold short. View Verrica Pharmaceuticals' Current Options Chain.

Some companies that are related to Verrica Pharmaceuticals include Cytokinetics (CYTK), Revance Therapeutics (RVNC), Phathom Pharmaceuticals (PHAT), Mersana Therapeutics (MRSN), Kiniksa Pharmaceuticals (KNSA), I-Mab (ARQT), Esperion Therapeutics (ESPR), MacroGenics (MGNX), Aimmune Therapeutics (AIMT), Phibro Animal Health (PAHC), Myovant Sciences (MYOV), INDIVIOR PLC/S (INVVY), Odonate Therapeutics (ODT), Rocket Pharmaceuticals (RCKT) and Enanta Pharmaceuticals (ENTA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include AbbVie (ABBV), Gilead Sciences (GILD), Aurora Cannabis (ACB), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Pfizer (PFE), Progenics Pharmaceuticals (PGNX), Exxon Mobil (XOM), Allergan (AGN) and Agile Therapeutics (AGRX).

(VRCA) raised $75 million in an IPO on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.82%), Kornitzer Capital Management Inc. KS (1.82%), Fosun International Ltd (1.26%), State Street Corp (0.91%), Geode Capital Management LLC (0.70%) and Nuveen Asset Management LLC (0.20%). Company insiders that own Verrica Pharmaceuticals stock include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View institutional ownership trends for Verrica Pharmaceuticals.

VRCA stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, Two Sigma Investments LP, Morgan Stanley, Squarepoint Ops LLC, Wells Fargo & Company MN, and UBS Group AG. View insider buying and selling activity for Verrica Pharmaceuticals.

VRCA stock was acquired by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., State Street Corp, Nuveen Asset Management LLC, Alliancebernstein L.P., BlackRock Inc., and Capital Investment Advisory Services LLC. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Chris Degnan, Joe Bonaccorso, Life Sciences Maste Perceptive, Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White. View insider buying and selling activity for Verrica Pharmaceuticals.

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VRCA stock can currently be purchased for approximately $11.48.

Verrica Pharmaceuticals has a market capitalization of $296.30 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe.

The official website for Verrica Pharmaceuticals is www.verrica.com.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected]